SG11201804412SA - Dimeric contrast agents - Google Patents
Dimeric contrast agentsInfo
- Publication number
- SG11201804412SA SG11201804412SA SG11201804412SA SG11201804412SA SG11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA SG 11201804412S A SG11201804412S A SG 11201804412SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- colleretto
- giacosa
- ribes
- crb
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 abstract 4
- 235000011483 Ribes Nutrition 0.000 abstract 3
- 241000220483 Ribes Species 0.000 abstract 3
- 210000000614 rib Anatomy 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229910021645 metal ion Inorganic materials 0.000 abstract 2
- 241001400064 Valeria Species 0.000 abstract 1
- 150000002678 macrocyclic compounds Chemical class 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000005298 paramagnetic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
- A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15199220 | 2015-12-10 | ||
| PCT/EP2016/080621 WO2017098044A1 (en) | 2015-12-10 | 2016-12-12 | Dimeric contrast agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804412SA true SG11201804412SA (en) | 2018-06-28 |
Family
ID=55027251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804412SA SG11201804412SA (en) | 2015-12-10 | 2016-12-12 | Dimeric contrast agents |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10407412B2 (pt) |
| EP (2) | EP3386954B1 (pt) |
| JP (1) | JP6896733B2 (pt) |
| KR (1) | KR102703336B1 (pt) |
| CN (1) | CN108368067B (pt) |
| AU (1) | AU2016368545C1 (pt) |
| BR (1) | BR112018010815B1 (pt) |
| CA (1) | CA3002897C (pt) |
| DK (2) | DK3386954T3 (pt) |
| ES (2) | ES2843998T3 (pt) |
| FI (1) | FI3753929T3 (pt) |
| HR (2) | HRP20221451T1 (pt) |
| HU (2) | HUE060536T2 (pt) |
| IL (1) | IL259836B (pt) |
| LT (1) | LT3386954T (pt) |
| MX (1) | MX2018007043A (pt) |
| PL (2) | PL3753929T3 (pt) |
| PT (1) | PT3386954T (pt) |
| RU (1) | RU2739834C2 (pt) |
| SG (1) | SG11201804412SA (pt) |
| SI (2) | SI3386954T1 (pt) |
| WO (1) | WO2017098044A1 (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| JP6896733B2 (ja) * | 2015-12-10 | 2021-06-30 | ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． | 二量体造影剤 |
| JP7034160B2 (ja) | 2016-11-28 | 2022-03-11 | バイエル・ファルマ・アクティエンゲゼルシャフト | 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物 |
| JP7145156B2 (ja) * | 2016-12-12 | 2022-09-30 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 二量体造影剤 |
| PE20211471A1 (es) | 2018-11-23 | 2021-08-05 | Bayer Ag | Formulacion de medios de contraste y proceso para prepararlos |
| IL293806A (en) | 2019-12-13 | 2022-08-01 | Bracco Imaging Spa | Production of protected do3a salts |
| BR112023000078A2 (pt) | 2020-07-27 | 2023-02-07 | Bracco Imaging Spa | Fabricação de agentes de contraste diméricos |
| CN116547271A (zh) * | 2020-12-04 | 2023-08-04 | 伯拉考成像股份公司 | 用于制备钆特醇的生产方法 |
| EP4377323A1 (en) * | 2021-07-27 | 2024-06-05 | Bracco Imaging SPA | Manufacturing of dimeric contrast agents |
| US20240299594A1 (en) | 2021-07-27 | 2024-09-12 | Bracco Imaging S.P.A. | Process for the manufacturing of a gadolinium complex solution |
| CN118401501A (zh) | 2021-12-14 | 2024-07-26 | 伯拉考成像股份公司 | 二聚体造影剂的制备 |
| KR20240119262A (ko) | 2021-12-14 | 2024-08-06 | 브라코 이미징 에스.피.에이. | 가돌리늄 착물의 이량체 거대고리 중간체를 포함하는 혼합물의 제조 방법 |
| WO2024074648A1 (en) | 2022-10-07 | 2024-04-11 | Bracco Imaging Spa | Precipitation and isolation of gadolinium complex |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4647447A (en) | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| IT1213029B (it) | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | Chelati di ioni metallici paramagnetici. |
| DE3625417C2 (de) * | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
| US5132409A (en) | 1987-01-12 | 1992-07-21 | Bracco Industria Chimica S.P.A. | Macrocyclic chelating agents and chelates thereof |
| GB9320277D0 (en) * | 1993-10-01 | 1993-11-17 | Nycomed Salutar Inc | Chelants |
| DE4009119A1 (de) | 1990-03-19 | 1991-09-26 | Schering Ag | 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| DE4035760A1 (de) * | 1990-11-08 | 1992-05-14 | Schering Ag | Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| DE4115789A1 (de) | 1991-05-10 | 1992-11-12 | Schering Ag | Makrocyclische polymer-komplexbildner, deren komplexe, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| DE4318369C1 (de) * | 1993-05-28 | 1995-02-09 | Schering Ag | Verwendung von makrocyclischen Metallkomplexen als Temperatursonden |
| GB9318550D0 (en) * | 1993-09-07 | 1993-10-20 | Nycomed Salutar Inc | Chelants |
| IT1291624B1 (it) | 1997-04-18 | 1999-01-11 | Bracco Spa | Chelati complessi di metalli paramagnetici a bassa tossicita' |
| DE19719033C1 (de) | 1997-04-29 | 1999-01-28 | Schering Ag | Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel |
| IT1292128B1 (it) | 1997-06-11 | 1999-01-25 | Bracco Spa | Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici |
| EP1032430A2 (en) * | 1997-11-17 | 2000-09-06 | Research Corporation Technologies, Inc. | Magnetic resonance imaging agents for the detection of physiological agents |
| DE19849465A1 (de) * | 1998-10-21 | 2000-04-27 | Schering Ag | Dimere Ionenpaare, Verfahren zu ihrer Herstellung und ihre Verwendung als Kontrastmittel |
| DE10117242C1 (de) * | 2001-04-06 | 2002-05-16 | Schering Ag | Unsymmetrische dimere Metallkomplexe, Liganden für diese Metallkomplexe, Verfahren zu deren Herstellung, Arzneimittel bzw. Diagnosemittel, die die Metallkomplexe enthalten, insbesondere Kontrastmittel |
| US6852854B1 (en) * | 2002-10-01 | 2005-02-08 | Psiloquest Inc. | Preformed carboxylated active ester for labeling biomolecules |
| US7208140B2 (en) | 2003-02-19 | 2007-04-24 | Schering Aktiengesellschaft | Trimeric macrocyclic substituted benzene derivatives |
| ATE430146T1 (de) * | 2004-07-02 | 2009-05-15 | Bracco Imaging Spa | Kontrastmittel mit hoher relaxivität zur verwendung in der magnetresonanzbilddarstellung (mri), enthaltend eine chelatbildende gruppe mit polyhydroxylierten substituenten |
| FR2891830B1 (fr) * | 2005-10-07 | 2011-06-24 | Guerbet Sa | Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale |
| RU2425831C2 (ru) * | 2005-12-02 | 2011-08-10 | Джи-И Хелткер АС | Мультимерные контрастные агенты для магнитного резонанса |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| EP2149567A1 (en) | 2008-07-18 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Cyclic polyamines for binding phosphatidylserine |
| EP2457594A1 (en) * | 2010-11-05 | 2012-05-30 | Bracco Imaging S.p.A | Cest systems exhibiting a concentration independent responsiveness |
| US9315524B2 (en) | 2012-05-07 | 2016-04-19 | Kumar Ranjan Bhushan | Magnetic resonance imaging agents for calcification |
| CN102727911B (zh) | 2012-07-09 | 2013-07-24 | 中国科学院长春应用化学研究所 | 双氨基聚乙二醇修饰的顺磁性金属配合物磁共振成像造影剂 |
| US9155804B2 (en) | 2012-09-26 | 2015-10-13 | General Electric Company | Contrast enhancement agents and method of use thereof |
| WO2015023979A1 (en) | 2013-08-16 | 2015-02-19 | Equip, Llc | Discrete peg constructs |
| JP6896733B2 (ja) * | 2015-12-10 | 2021-06-30 | ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． | 二量体造影剤 |
-
2016
- 2016-12-12 JP JP2018530018A patent/JP6896733B2/ja active Active
- 2016-12-12 PL PL20187182.9T patent/PL3753929T3/pl unknown
- 2016-12-12 CN CN201680071558.6A patent/CN108368067B/zh active Active
- 2016-12-12 ES ES16810346T patent/ES2843998T3/es active Active
- 2016-12-12 HU HUE20187182A patent/HUE060536T2/hu unknown
- 2016-12-12 DK DK16810346.3T patent/DK3386954T3/da active
- 2016-12-12 SI SI201631038T patent/SI3386954T1/sl unknown
- 2016-12-12 FI FIEP20187182.9T patent/FI3753929T3/fi not_active Application Discontinuation
- 2016-12-12 ES ES20187182T patent/ES2932302T3/es active Active
- 2016-12-12 PL PL16810346T patent/PL3386954T3/pl unknown
- 2016-12-12 EP EP16810346.3A patent/EP3386954B1/en active Active
- 2016-12-12 WO PCT/EP2016/080621 patent/WO2017098044A1/en active Application Filing
- 2016-12-12 SI SI201631639T patent/SI3753929T1/sl unknown
- 2016-12-12 HU HUE16810346A patent/HUE052680T2/hu unknown
- 2016-12-12 PT PT168103463T patent/PT3386954T/pt unknown
- 2016-12-12 SG SG11201804412SA patent/SG11201804412SA/en unknown
- 2016-12-12 RU RU2018123572A patent/RU2739834C2/ru active
- 2016-12-12 EP EP20187182.9A patent/EP3753929B1/en active Active
- 2016-12-12 AU AU2016368545A patent/AU2016368545C1/en active Active
- 2016-12-12 US US16/060,754 patent/US10407412B2/en active Active
- 2016-12-12 HR HRP20221451TT patent/HRP20221451T1/hr unknown
- 2016-12-12 CA CA3002897A patent/CA3002897C/en active Active
- 2016-12-12 KR KR1020187016958A patent/KR102703336B1/ko active IP Right Grant
- 2016-12-12 DK DK20187182.9T patent/DK3753929T3/da active
- 2016-12-12 MX MX2018007043A patent/MX2018007043A/es unknown
- 2016-12-12 LT LTEP16810346.3T patent/LT3386954T/lt unknown
- 2016-12-12 BR BR112018010815-4A patent/BR112018010815B1/pt active IP Right Grant
-
2018
- 2018-06-05 IL IL259836A patent/IL259836B/en unknown
-
2019
- 2019-07-25 US US16/522,076 patent/US10882849B2/en active Active
-
2020
- 2020-10-01 US US17/060,396 patent/US11401262B2/en active Active
-
2021
- 2021-01-13 HR HRP20210061TT patent/HRP20210061T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804412SA (en) | Dimeric contrast agents | |
| SG11201804415QA (en) | Contrast agents | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201407898WA (en) | Electrode testing apparatus | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201408261UA (en) | Syringe | |
| SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201909003YA (en) | Integrated vascular access device and anchor pad | |
| SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201807250PA (en) | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors |